(Total Views: 67)
Posted On: 12/17/2024 12:32:37 PM
Post# of 2923

$DYAI Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology https://finance.yahoo.com/news/dyadic-receive...00271.html

